COVID-19: Immunology and treatment options
S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of esca** innate …
protective immunity does not exist in humans and the virus is capable of esca** innate …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …
Antiviral approaches against influenza virus
Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …
Critical care management of adults with community-acquired severe respiratory viral infection
With the expanding use of molecular assays, viral pathogens are increasingly recognized
among critically ill adult patients with community-acquired severe respiratory illness; studies …
among critically ill adult patients with community-acquired severe respiratory illness; studies …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
SJ Valk, C Kimber, E Dorando, I Monsef… - Cochrane Database …, 2021 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are being investigated as potential therapies …
in patients with viral respiratory diseases, and are being investigated as potential therapies …
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
S Ravichandran, EM Coyle, L Klenow, J Tang… - Science translational …, 2020 - science.org
Multiple vaccine candidates against SARS-CoV-2 based on viral spike protein are under
development. However, there is limited information on the quality of antibody responses …
development. However, there is limited information on the quality of antibody responses …
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
N Gharebaghi, R Nejadrahim, SJ Mousavi… - BMC infectious …, 2020 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) has infected people in many
countries worldwide. Discovering an effective treatment for this disease, particularly in …
countries worldwide. Discovering an effective treatment for this disease, particularly in …
Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome–
related coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the …
related coronavirus 2 (SARS-CoV-2) will be critical for the public health response to the …
Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection
Background A synergistic effect of combination therapy with favipiravir and oseltamivir has
been reported in preclinical models of influenza. However, no data are available on the …
been reported in preclinical models of influenza. However, no data are available on the …